Articles tagged with Influenza Viruses
A Duke University researcher has developed a two-tiered model to simulate the interplay between epidemiological dynamics and evolutionary changes in flu viruses. The model focuses on understanding how flu evolves differently in humans versus animals, with potential implications for developing more effective vaccines.
The 1918 influenza pandemic created a viral dynasty that persists to this day, with all human-adapted influenza A viruses being descendents of the founding virus. The novel 2009 H1N1 virus is yet another manifestation of this enduring viral family.
Researchers at Medical College of Wisconsin published first paper describing Milwaukee's largest swine origin influenza (H1N1) outbreak in June 2009. The study identified 679 adults and children with S-OIV infection, making up 18.2% of all tested individuals.
A review by Dr David Fedson suggests that generic drugs like statins and fibrates could help manage the pandemic by regulating cell signalling pathways. However, the majority of the world's population will not have timely access to affordable supplies of vaccines and antiviral agents.
A new diagnostic test using RT-PCR technology has been developed to detect both seasonal influenza A virus and the emerging H1N1 swine-derived influenza A virus in human clinical samples. The test is fast, sensitive, and cost-effective, allowing for rapid identification of infected individuals and expedited antiviral therapy.
A study in mice reveals that type I IFNs compromise the body's ability to mount an effective immune response against bacterial infections after influenza. This finding may lead to new avenues for developing treatments to combat post-influenza bacterial pneumonia.
Researchers at the University of Maryland School of Medicine found that Abatacept reduces severe illness and death in mice exposed to Influenza A virus by tempering the immune response. The treatment approach also improves survival rates for mice infected with a lethal dose of influenza virus.
Researchers at the Bioinformatics Institute in Singapore have created a 3D structural model of the neuraminidase protein, which is critical to the H1N1 influenza A virus. This breakthrough analysis revealed extensive surface mutations compared to closely related strains, making previous flu vaccinations less effective. The study also f...
Recent research on H5N1 avian influenza virus reveals its mechanisms, epidemiology, and transmission dynamics. Understanding the host-virus interaction is crucial for developing effective control measures.
Researchers at USC have identified a critical molecular mechanism that allows the influenza virus to evade the body's immune response system. The study reveals that the virus targets the ubiquitin ligase TRIM25, inhibiting its ability to activate RIG-I and trigger an alarm signal.
Research suggests that avian influenza viruses struggle to grow and spread in the human nose due to its cooler temperature, making it less likely to cause respiratory illness. The study also found that mutated viruses with proteins from avian influenza viruses are unlikely to thrive at human nose temperatures.
Researchers developed a mathematical model to predict immune responses to influenza A viruses, including novel strains like H1N1. The model suggests that prolonged infection limits T cell production and antigen presentation, making antiviral therapy most effective within two days after infection.
The InDevR FluChip has been shown to detect and distinguish swine-origin H1N1 from human influenza viruses with high accuracy. The assay's robust performance is attributed to its targeted M-gene sequence, which codes for the virus' matrix proteins.
Researchers discovered that the influenza virus can paralyze the immune systems of healthy individuals, leading to severe secondary bacterial infections like pneumonia. The study found that this immunological paralysis is long-lived and specific to influenza infection.
A French study analyzed mortality rates in three-quarters of the European population, concluding that the virus likely originated outside Europe. The research found high synchronicity among the 14 studied countries, with a peak in October-November 1918.
The FluChip technology has been licensed by InDevR to detect the deadly flu virus. The test can distinguish between human H1N1 viruses and the new swine H1N1 subtype, a crucial gap in current diagnostics. This new tool has the potential to greatly enhance influenza surveillance and track the virus.
A new study found that early prenatal exposure to the Hong Kong flu may have interfered with fetal cerebral development and caused reduced intelligence in adulthood. The study involved over 180,000 men born between 1967 and 1973 and showed a significant association between prenatal exposure to the virus and lower intelligence scores.
A study found that drug-resistant influenza A(H1N1) viruses carrying a neuraminidase gene mutation can retain significant transmissibility and pathogenicity in hospitalized patients. These viruses have been linked to severe illnesses and deaths in immunocompromised individuals.
A recent study reports a significant increase in oseltamivir-resistant influenza A viruses, posing a challenge to treatment and vaccination strategies. The study found that resistant cases had similar demographic characteristics as susceptible cases, but no association with oseltamivir use.
The discovery of the CR6261 antibody is good news for researchers aiming to design a universal flu vaccine. The antibody has the potential to treat unvaccinated individuals infected with the flu and provides broad protection against various influenza viruses, including pandemic strains.
Researchers identified human monoclonal antibodies that can neutralize a broad range of influenza A viruses, including seasonal and pandemic flu strains. These antibodies offer potential for treatment and prevention of the flu during outbreaks or pandemics.
Researchers identified human monoclonal antibodies that bind to the stem of H5 type hemaglutinin, preventing viral entry into host cells. These antibodies offer potential cross-protection against various flu strains, including bird and seasonal influenza viruses.
Researchers at Dana-Farber Cancer Institute identified human monoclonal antibodies that neutralize a broad range of influenza A viruses, including avian and seasonal flu. The antibodies bind to the conserved stem region of the virus, preventing viral entry into host cells.
Researchers found a significant correlation between low absolute humidity and increased influenza virus survival and transmission. The study, published in PNAS, suggests that absolute humidity is the key control for seasonal flu outbreaks.
Researchers at EMBL have discovered a promising drug target in influenza virus, specifically the PA subunit responsible for cleaving host RNA caps. This finding provides new insights into the cap snatching mechanism that allows the virus to hijack human cells and multiply.
Researchers have found that adding a new component to vaccines for influenza might enable broad protection against avian and seasonal influenza A viruses. Memory T cells from individuals infected with seasonal influenza A cross-react with H5N1, suggesting improved immunity.
The majority of deaths during the 1918-1919 influenza pandemic were not caused by the flu virus alone, but rather bacterial pneumonia that developed after the virus destroyed the cells lining the bronchial tubes. Comprehensive pandemic preparations should include provisions to stockpile antibiotics and bacterial vaccines.
Researchers have developed a rapid way to produce human monoclonal antibodies against the flu, overcoming technical barriers that slowed their development. The new technique could potentially be used for diagnosis and treatment of other infectious diseases.
A bird-flu pandemic will likely be controlled through widespread vaccination, which must be broadly-protective and rapidly produced. The virus is highly pathogenic in humans, with a mortality rate over 60%. Improving diagnostic tools and treatment options are also crucial to managing the disease.
Researchers analyzed gene sequences of seasonal influenza virus samples collected from temperate regions and found that new strains emerge annually from the tropics. This understanding can help public health officials develop more accurate flu vaccine strategies.
Researchers have identified a tropical source for the influenza A virus, which infects North Americans each winter and causes an average of 36,000 deaths. The study found that two strains of the virus, H3N2 and H1N1, follow a distinct pattern in their seasonal emergence and evolution.
Researchers analyzed 13,000 virus samples from 2002 to 2007 to understand migration patterns of seasonal flu. They found that East and Southeast Asia serves as a source for influenza A (H3N2) viruses globally, with new strains emerging in the region before spreading to other parts of the world.
A study found that flu viruses originating in East and Southeast Asia spread globally, with strains emerging in Asia first, followed by Europe and North America. The research aims to improve flu vaccine design by focusing surveillance efforts on these regions.
The study found that key codons responsible for antigenic drift were identified in the HA1 gene of H3N2 influenza viruses. The mutations occurred over eight flu seasons and affected four times of antigenic drift in Fujian, China.
Researchers found evidence of canine influenza virus circulation in the greyhound population dating back to 1999. The discovery sheds light on a potential earlier introduction of the virus, which may have caused respiratory outbreaks at racing tracks.
Researchers found that genetic material exchange between closely related influenza A virus strains may have caused the 1947 and 1951 human flu epidemics, challenging the long-held belief that reassortment events lead to severe pandemics.
Researchers found that genetic reassortment events led to the creation of new hybrid viruses in humans during severe influenza epidemics in 1947 and 1951. This challenges the standard model of human influenza virus evolution, suggesting a more complex co-circulation of multiple forms of the same strain.
Researchers found that influenza vaccine is less effective in rural children of Gabon compared to semi-urban counterparts due to co-infections and poor nutrition. This study highlights the need for tailored approaches to pandemic influenza prevention in developing countries.
Researchers found that influenza vaccine was more effective in a semi-urban population than in a rural population of schoolchildren in Gabon, Africa. Infection with parasites and/or poor nutrition may compromise immune responses to the flu vaccine.
The structure of hemagglutinin on influenza B virus provides key insights into potential mutations that could spark a pandemic. By comparing it to a similar protein on influenza A virus, researchers may be able to understand the changes needed for avian flu to infect humans.
A recent study published in Cell Host & Microbe has found that the protein PB1-F2 from the 1918 influenza virus strain increases virulence and secondary bacterial pneumonia in mouse models. This discovery provides crucial insights into the pathogenicity of IAVs and has significant implications for preparing for future pandemics.
Human and avian influenza viruses target different cells in the lower respiratory tract, with human virus targeting upper respiratory tract cells and avian virus targeting deeper lung cells. The study provides insights into the pathogenesis of these divergent diseases.
A study found that Tamiflu is not removed or degraded during normal sewage treatment, leading to high levels of the drug in surrounding waters. This increases the risk of influenza viruses developing resistance to the medication, posing a threat to public health.
Scientists at St. Jude Children's Research Hospital have found specific mutations that distinguish influenza viruses in birds from those that infect humans. These markers can be used to track changes in H5N1 avian influenza strains threatening humans, suggesting potential adaptation and spread.
A team of scientists at NIAID has developed a strategy to generate vaccines and therapeutic antibodies that can target predicted H5N1 mutants before they emerge. By identifying key mutations in the HA protein, they created vaccines and isolated new antibodies that could neutralize both bird- and human-adapted forms of the virus.
Researchers analyzed emergency department fever and respiratory complaint data to determine influenza-related morbidity by age. The study found that surveillance using electronic data can provide timely and representative information about circulating influenza viruses, with significant age-specific differences.
Scientists are testing a universal flu vaccine that targets all 'A' strains of the virus, offering broad and lifelong protection. The vaccine has shown promising results in laboratory animals and is now being administered to a small group of healthy people in Phase I clinical trials.
Scientists discovered preserved samples of the 1918 influenza virus in frozen autopsy tissues from an Alaskan woman buried for over 75 years. The recovery enabled researchers to study the virus's genetic material, providing valuable insights into its structure and potential vulnerabilities.
Experts argue that researchers should focus broadly on influenza viruses, improving knowledge of basic biological means, enhancing surveillance, and developing new antivirals and diagnostics. This approach can also help combat seasonal influenza, a major public health concern in the US.
A new experimental flu vaccine produced using insect cells has shown promising results in early testing, demonstrating safety and immunogenic response in healthy adults. The vaccine, made using recombinant DNA techniques, offers a potential alternative to traditional egg-based vaccines.
A recent study in Japan found partial resistance to neuraminidase inhibitors among influenza B viruses, which may have implications for treatment and prevention strategies. The emergence of these resistant variants poses a significant concern, as they can cause infections with no difference in duration or clinical outcome.
The NIAID is awarding $23 million per year for seven years to establish six Centers of Excellence for Influenza Research and Surveillance. These centers will bolster influenza research in key areas, including understanding how the virus causes disease and how the human immune system responds to infection with the virus.
UC Davis has been named a partner in a new $18.5 million national research center to study influenza viruses with pandemic potential. The Center for Rapid Influenza Surveillance and Research will expand the federal government's early-detection program for influenza and help reduce the chances of deadly outbreaks.
The University of Minnesota will receive funding to monitor domestic and international wild bird populations for avian influenza viruses, aiming to rapidly identify pandemic threats. The center's research will support public health strategies for controlling the impact of an influenza pandemic.
The University of Alaska Fairbanks will collect and test over 8,000 samples from Alaska and Russia to understand the genetic changes of flu viruses and their success in animal hosts. The research aims to develop new knowledge on the ecology of the influenza virus and its impact on bird populations.
The UGA-Emory collaboration will study influenza virus adaptation, transmission, and human immune responses. Researchers will also explore the genetic factors of flu spread and develop new antivirals.
Researchers found that modifying the 1918 flu virus's hemagglutinin receptor binding site reduced its ability to transmit in ferrets. The study suggests that understanding this molecular mechanism could lead to the development of novel drugs to stop influenza transmission and prevent epidemics.
Researchers found that the 1918 flu virus triggers a deadly respiratory infection by attacking the lungs, leading to death. The study provides insight into how the virus killed so quickly and efficiently, offering potential clues for developing novel antiviral strategies.
Researchers found antiviral drugs highly effective in preventing seasonal flu illness, with oseltamivir at 81% efficacy. Treatment also reduced infectiousness, particularly with oseltamivir, but further studies are needed to confirm results.
Researchers found hundreds of shared epitopes among different virus strains, including conserved regions between avian and human viruses. The study provides key insights into how the immune system recognizes influenza viruses, shedding light on gaps in knowledge and potential vaccine targets.